Name: Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Pharmacodynamics
Published: 2026-09-17T18:16:06-04:00

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

5 evidence topics · 4 sources

Preclinical: VEGFR2 inhibitory concentration

“for vorolanib (52nM; 23 ng/mL) and axitinib (0.2nM; 0.07 ng/mL)” (opens the source at this quote in a new tab)

Preclinical: angiogenesis and melanin binding

“All three TKIs effectively inhibited angiogenesis in vitro. In vivo, TKIs were more effective at inhibiting VEGF-induced angiogenesis than the anti-VEGF antibody bevacizumab. Of the three TKIs, only sunitinib bound melanin.” (opens the source at this quote in a new tab)

Preclinical: IL-6 signaling and neuroprotection

“data showed a reduction in IL-6 activity of more than 50% associated with vorolanib, the active ingredient in DURAVYU, via inhibition of JAK1, suggesting anti-inflammatory properties.” (opens the source at this quote in a new tab)
“Vorolanib has also demonstrated neuroprotection in an in-vivo model of retinal detachment.” (opens the source at this quote in a new tab)

Preclinical: time to target tissue concentrations in rabbits

“Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations exceeding IC50 in the choroid and retina within hours of administration.” (opens the source at this quote in a new tab)

Preclinical: oral vorolanib in choroidal and retinal neovascularization models

“Oral X-82 was found to inhibit Matrigel-induced choroidal neovascularization in a rat model.” (opens the source at this quote in a new tab)
“An oxygen-induced ischemic retinopathy mouse model also showed potent inhibition of retinal neovascularization, with cell culture studies suggesting similar antiangiogenic activity to sunitinib.” (opens the source at this quote in a new tab)